NASDAQ:EVO - Nasdaq - US30050E1055 - ADR - Currency: USD
Taking everything into account, EVO scores 3 out of 10 in our fundamental rating. EVO was compared to 55 industry peers in the Life Sciences Tools & Services industry. EVO has a bad profitability rating. Also its financial health evaluation is rather negative. EVO is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -10.64% | ||
ROE | -22.69% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 13.62% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.46 | ||
Debt/FCF | N/A | ||
Altman-Z | 0.85 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.03 | ||
Quick Ratio | 1.93 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 67.35 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
4.73
+0.7 (+17.37%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 1.89 | ||
P/FCF | N/A | ||
P/OCF | 42.97 | ||
P/B | 1.63 | ||
P/tB | 2.46 | ||
EV/EBITDA | 67.35 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -10.64% | ||
ROE | -22.69% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 13.62% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.46 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 18.85 | ||
Cap/Depr | 113.07% | ||
Cap/Sales | 14.58% | ||
Interest Coverage | N/A | ||
Cash Conversion | 156.03% | ||
Profit Quality | N/A | ||
Current Ratio | 2.03 | ||
Quick Ratio | 1.93 | ||
Altman-Z | 0.85 |